Ipamorelin is a pentapeptide growth hormone secretagogue that acts through the ghrelin receptor (GHS-R1a). It is notable for its high selectivity — it stimulates growth hormone release without significantly affecting cortisol, prolactin, or aldosterone levels at research doses.
Selectivity Mechanism
Unlike other GHS-R1a agonists such as GHRP-6 and GHRP-2, ipamorelin does not activate the HPA axis or lipogenic pathways at equivalent GH-releasing doses. This selectivity is attributed to its specific binding orientation within the GHS-R1a binding pocket.
CJC-1295 Combination Research
Ipamorelin is frequently studied in combination with CJC-1295 (with or without DAC). The rationale is that CJC-1295 amplifies the GH-releasing pulse initiated by ipamorelin through GHRH receptor activation, while ipamorelin provides the acute secretagogue signal through the ghrelin receptor.